Organization (Nonprofit)
Southern California Institute for Research and Education
ClinicalTrials.gov lists Southern California Institute for Research and Education as lead sponsor of 26 trials. It has 13 active development programs and 20 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Southern California Institute for Research and Education: 26 lead-sponsored trials and 1 legal-entity registration.
Disease areas (39)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 3 |
| HIV Infections | 3 |
| Stress Disorders, Post-Traumatic | 3 |
| Diabetic Neuropathies | 2 |
| Sleep Apnea Syndromes | 2 |
Showing 5 of 39 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2018 | 1 |
| 2015 | 2 |
| 2014 | 4 |
| 2013 | 2 |
| 2012 | 5 |
| 2010 | 1 |
| 2009 | 3 |
| 2008 | 4 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: none of the 26 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (13)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Rilonacept | Hepatitis, Alcoholic | Phase 2 | 1 |
| Mycophenolate Mofetil | Substance-Related Disorders | Phase 2 | 1 |
| Mycophenolate Mofetil | Liver Diseases, Alcoholic | Phase 2 | 1 |
| Mycophenolate Mofetil | Hepatitis, Alcoholic | Phase 2 | 1 |
| Rilonacept | Liver Diseases, Alcoholic | Phase 2 | 1 |
Showing 5 of 13 active programs.
Approved assets (20)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ramelteon | 2 |
| Lorcaserin | 1 |
| TREATMENT | 1 |
| Betaine | 2 |
| Mycophenolate Mofetil | 1 |
Showing 5 of 20 approved assets.
Journals published in (69)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Gait & posture | 11 |
| Archives of physical medicine and rehabilitation | 9 |
| Journal of rehabilitation research and development | 7 |
| Prosthetics and orthotics international | 7 |
| Diabetes care | 6 |
Showing 5 of 69 journals.
Organization relationships (4)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 1 |
| Hologenix, LLC | Co sponsors trial with | 1 |
| PEMF Systems, Inc. | Co sponsors trial with | 1 |
| Heritage Medical Research Institute | Co sponsors trial with | 1 |
Latest dated events (28)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-05-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2018-05-19 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2015-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2015-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 28 events.
Biomarker capability evidence (26)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| NADK | Trial sponsor | Named in trial inclusion criteria |
| PDXP | Trial sponsor | Named in trial inclusion criteria |
| PLP1 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 26 evidence rows.
Biomarkers this organization publishes on (1)
| Biomarker | Publications |
|---|---|
| BCHE | 1 |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.